Chandigarh

BEST RESEARCH PAPER AWARD FOR PU

June 02, 2020 07:39 PM

Chandigarh (Face2News)

Dr Bhupinder Singh Bhoop, Professor at the University Institute of Pharmaceutical Sciences (UIPS), and Coordinator, UGC Centre of Excellence in Nano Biomedical Applications, Panjab University (PU), Chandigarh, along with his team, has recently been selected for the coveted “BEST RESEARCH PAPER AWARD” for their research manuscript entitled, "Supersaturated LFCS Type III Self-Emulsifying Delivery Systems of Sorafenib with Improved Biopharmaceutical Performance: QbD-Enabled Development and Evaluation”.

The entire research work encompassed in the said paper has been carried out meticulously by Ms Teenu Sharma, a DST-Inspire Meritorious Doctoral Research Fellow working in UIPS on anticancer drug delivery research under the supervision of Professor Bhoop and Professor O P Katare.

  
In a communiqué received from the Editor-in-Chief ,Prof. Maria José Alonso of the Drug Delivery and Translational Research (DDTR) Journal, Professor Bhoop was congratulated through an email for the GREAT SCIENCES PRESENTED IN THE PAPER in the Special Issue of DDTR, focused on the theme, “Drug Delivery Systems: From Basic Sciences to Clinical Translation”.

DDTR is an official journal of Controlled Release Society, USA, and is published by M/s Springer, USA, with five years' Thomson-Reuters Impact Factor of 3.35. CRS is a highly prestigious scientific organization dedicated on providing a unique forum for publication of high-quality research, particularly on the translational aspects of drug delivery.

The selected paper will be announced and featured in the Springer and CRS web sites, and in their media tools like, Twitter, LinkedIn and Facebook. Also, an illustrative image of the research work would adorn the TITLE PAGE of the journal as a matter of recognition.

The aforesaid research work demonstrates the successful and systematic development of an efficient lipidic delivery system of sorafenib, a popular drug used against liver cancer, resulting in its improved chemotherapeutic potential, safety and patient compliance.

Have something to say? Post your comment
Copyright © 2017, Face 2 News, All rights reserved. Terms & Conditions Privacy Policy Disclaimers